Should PD-L1 be Used as a Biomarker for Immunotherapy in Lung Cancer?
Nov 11, 2015 ·
5m 5s
Download and listen anywhere
Download your favorite episodes and enjoy them, wherever you are! Sign up or log in now to access offline listening.
Description
Dr. Eddie Garon, UCLA, reviews the controversial question of whether PD-L1 expression is a reliable enough biomarker to be used to select patients to receive or not receive immune checkpoint...
show more
Dr. Eddie Garon, UCLA, reviews the controversial question of whether PD-L1 expression is a reliable enough biomarker to be used to select patients to receive or not receive immune checkpoint inhibitor therapy in lung cancer.
show less
Information
| Author | cancerGRACE |
| Organization | cancerGRACE |
| Website | - |
| Tags |
Copyright 2024 - Spreaker Inc. an iHeartMedia Company
Comments